UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 11, 2003

Aastrom Biosciences, Inc.

(Exact name of registrant as specified in charter)

Michigan	0-22025	94-3096597
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor Michigan	48106
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (734) 930-5555

Not Applicable

(Former name or former address, if changed since last report)

TABLE OF CONTENTS

	Item 5. Other Events.
	Item 7. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 5. Other Events.

On December 11, 2003, Aastrom Biosciences issued a press release relating to the initiation of a Phase I clinical trial, in collaboration with investigators at Duke University Medical Center, to evaluate a dendritic cell-based vaccine as a new treatment for an assortment of gastro-intestinal system cancers. The press release is attached as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

Exhibit
No.	Description
99.1	Press Release of December 11, 2003 relating to the initiation of a Phase I clinical trial, in collaboration with investigators at Duke University Medical Center, to evaluate a dendritic cell-based vaccine as a new treatment for an assortment of gastro-intestinal system cancers.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aastrom Biosciences, Inc.
Date: December 11, 2003	By:	/s/ Alan M. Wright
		Senior Vice President, Administrative and Financial Operations, CFO

EXHIBIT INDEX

Exhibit
No.	Description
99.1	Press Release of December 11, 2003 relating to the initiation of a Phase I clinical trial, in collaboration with investigators at Duke University Medical Center, to evaluate a dendritic cell-based vaccine as a new treatment for an assortment of gastro-intestinal system cancers.